Comparing Insmed (NASDAQ:INSM) and Shuttle Pharmaceuticals (NASDAQ:SHPH)

Shuttle Pharmaceuticals (NASDAQ:SHPH) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Profitability

This table compares Shuttle Pharmaceuticals and Insmed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-583.02%	-258.92%
Insmed	-252.01%	N/A	-54.43%

Volatility & Risk

Shuttle Pharmaceuticals has a beta of -1.75, indicating that its stock price is 275% less volatile than the S&P 500. Comparatively, Insmed has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.

Earnings & Valuation

This table compares Shuttle Pharmaceuticals and Insmed”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$6.59 million	($4.15)	-0.17
Insmed	$305.21 million	46.66	-$749.57 million	($5.55)	-14.34

Shuttle Pharmaceuticals has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Shuttle Pharmaceuticals and Insmed, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	0	0	0	0	0.00
Insmed	0	0	16	0	3.00

Insmed has a consensus target price of $85.60, indicating a potential upside of 7.54%. Given Insmed’s stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Shuttle Pharmaceuticals.

Institutional & Insider Ownership

4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. 39.6% of Shuttle Pharmaceuticals shares are owned by company insiders. Comparatively, 4.6% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Insmed beats Shuttle Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.